DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Conditions: Diffuse Large B Cell Lymphoma

First Posted Date: 2020-07-29

Last Posted Date: 2020-07-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 407

Registration Number: NCT04491721

Locations: 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Comparison of Two Bending Angles for Nasotracheal Intubation With a Malleable Vedio Stylet

Not Applicable

Completed

Conditions: Intubation;Difficult

Interventions: Device: bending angle

First Posted Date: 2020-07-07

Last Posted Date: 2021-01-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 98

Registration Number: NCT04459481

Locations: 🇨🇳
ChineseAMS, Beijing, Beijing, China

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: oral etoposide + anlotinib

First Posted Date: 2020-06-30

Last Posted Date: 2021-07-21

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT04452370

Locations: 🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, China

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Phase 2

Conditions: Sarcoma

Interventions: Drug: Camrelizumab and Apatinib

First Posted Date: 2020-06-25

Last Posted Date: 2020-06-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT04447274

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Epirubicin or Pirarubicin
Drug: Cyclophosphamide

First Posted Date: 2020-06-18

Last Posted Date: 2020-06-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 286

Registration Number: NCT04437160

Locations: 🇨🇳
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Phase 2

Conditions: Rituximab
Diffuse Large B-cell Lymphoma
Toripalimab

Interventions: Drug: Toripalimab combine with Rituximab

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT04425824

Locations: 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: nab-paclitaxel
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2020-05-18

Last Posted Date: 2022-03-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 70

Registration Number: NCT04390958

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Cancer
Colorectal Cancer
Colorectal Adenocarcinoma

Interventions: Drug: XELOXIRI/Bevacizumab

First Posted Date: 2020-05-08

Last Posted Date: 2020-05-08

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 106

Registration Number: NCT04380103

Locations: 🇨🇳
National Center/Cancer Hospital, China Academy of Medical Science and Peking Union Medical College, Beijing, China
🇨🇳
National Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Conditions: Platinum-resistant Recurrent Ovarian Cancer

Interventions: Drug: PLD 40mg/m2 ivgtt q4w
Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd

First Posted Date: 2020-04-15

Last Posted Date: 2022-03-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 152

Registration Number: NCT04348032

Locations: 🇨🇳
National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Hubei Cancer Hospital, Hubei, Hubei, China

and more 13 locations

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Phase 3

Conditions: Breast Cancer

Interventions: Radiation: internal mammary nodal irradiation
Radiation: no internal mammary nodal irradiation

First Posted Date: 2020-03-25

Last Posted Date: 2022-01-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT04320979

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy